Two pairs of parental vs. cisplatin resistant human NSCLC cells (A vs. ALC and FA vs. FC) and a pair of mouse Lewis lung cells (LLC vs. LLC-CR) were used. Cell line “A” was established with pleural fluid from a patient with adenocarcinoma. FA was established from a poorly differentiated squamous cell carcinoma. Cellular characteristics have been previously characterized (22 (link)–25 (link)) and routinely tested for mycoplasma infection (MycoAlert; Lonza cat#LT07–710). These cell lines were not derived from the patients reported here in this study. LLC and LL24 were purchased (ATCC). We established their cisplatin resistant variants using previously published methods (23 (link), 24 (link)). Note: ALC and FC exhibit 7 fold resistance to cisplatin. LLC-CR exhibits 3 fold resistance. LL24 is normal lung fibroblast. Supplementary Table1 shows the ID50 values for the sensitive and resistant cell lines. Recombinant human IFNγ was purchased from Biolegend (cat#570204). IDO1 inhibitors (Epacadostat (cat#T3545), PF-06840003 (cat#T4307), NLG-919 (cat#T1806), and Indoximod (cat# T6543)) were purchased from TargetMol. Dimethoxyflavone (DMF; cat#D6571), CH-223191 (cat#C8124), TIRON (4,5-dihydroxy-1,3-benzenedisulfonic; cat#172553), and NAD+ were purchased from Sigma.
Protocol detail
Cisplatin Resistance in NSCLC Cells
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Adenocarcinoma
Cell lines
Cellular
Ch 223191
Cisplatin
Epacadostat
Fibroblast
Human
Ifnγ
Indoximod
Inhibitors
Lung
Mouse
Mycoplasma infection
Nlg 919
Nsclc
Parental
Patients
Pf 06840003
Pleural
Squamous cell carcinoma
Tiron
Corresponding Organization :
Other organizations : Miami VA Healthcare System, University of Miami
Top 5 similar protocols
Protocol cited in 1 other protocol
Variable analysis
independent variables
- Cell lines (A vs. ALC, FA vs. FC, LLC vs. LLC-CR)
- Recombinant human IFNγ
- IDO1 inhibitors (Epacadostat, PF-06840003, NLG-919, and Indoximod)
- Dimethoxyflavone (DMF), CH-223191, TIRON, and NAD+
- Cellular characteristics
- Cisplatin resistance level (ID50 values)
- Mycoplasma infection testing (MycoAlert; Lonza)
- LL24 (normal lung fibroblast)
- Positive controls: Not explicitly mentioned
- Negative controls: LL24 (normal lung fibroblast)
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!